Financial Wire

James Hardie Industries Under Law Firm Investigation Over Potential Disclosure Failures

-- James Hardie Industries (ASX:JHX) is being investigated by law firm Maurice Blackburn over potential disclosure failures ahead of the release of its fiscal first-quarter 2026 results, which precipitated a 34% decline in its Australia-listed shares over two trading days in August 2025, the law firm said.

Maurice Blackburn said the company in May 2025 guided for fiscal 2026 organic sales and earnings before interest, taxes, depreciation, and amortization growth across all regions, but in August 2025 reported weaker-than-expected quarterly results that included a fall in earnings and net sales.

"Our investigation concerns whether James Hardie engaged in misleading or deceptive conduct and/or breached its continuous disclosure obligations by failing to disclose material issues affecting its North American Fiber Cement segment," Maurice Blackburn said.

James Hardie Industries did not immediately respond to a request for comment from.

The company's shares were gaining more than 1% in recent Tuesday trade.

Related Articles

Asia

Huadian New Energy 2025 Profit Down 18%, Revenue Up 15%

Huadian New Energy (SHA:600930) posted 2025 attributable net profit of 7.26 billion yuan, down 18% from 8.83 billion yuan the previous year.Earnings per share slipped to 0.18 yuan from 0.24 yuan, according to a filing with the Shanghai bourse.Operating revenue rose 15% year over year to 39.0 billion yuan from 34.0 billion yuan.Shares of the power company were down 1% in recent trade.

$SHA:600930
Asia

National Storage REIT Says New South Wales Court Approves Brookfield, GIC Takeover Scheme

National Storage REIT (ASX:NSR) confirmed that the Supreme Court of New South Wales has approved the share scheme of arrangement and granted judicial advice for the trust scheme, enabling a Brookfield Funds and GIC-led consortium to proceed with the acquisition of all the company stapled securities, according to a Tuesday Australian bourse filing.The schemes are now legally effective following lodgment with the Australian Securities and Investments Commission, and the company's securities are expected to be suspended from trading at the close of trading on Tuesday, per the filing.The scheme record date is April 29, with implementation scheduled for May 8, when security holders will receive the scheme consideration, the filing added.

$ASX:NSR
Asia

Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%

Starpharma Holdings (ASX:SPL) has received positive feedback from the US Food and Drug Administration (FDA) on the proposed design of its first-in-human phase 1 clinical study of the DEP HER2 radiotherapy candidate, according to a Tuesday filing with the Australian bourse.The company is developing the candidate to treat certain gastric/gastro-oesophageal junction cancers and other advanced cancers in patients who have previously received targeted therapy.The US FDA feedback supports plans to launch the phase one study, which is on track to begin in the second half of the year.The FDA also confirmed that the radiotherapy candidate is targeting a population with a significant unmet medical need, indicating the potential for a fast-track designation or other accelerated development pathways, Starpharma said.The company's shares were 7% higher in recent Tuesday trade.

$ASX:SPL